^
+ Follow IMATINIB Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1344307
                    [Title] => Access program helps poor cancer patients get treatment
                    [Summary] => 

A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.

[DatePublished] => 2014-07-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => http://media.philstar.com/images/the-philippine-star/business/science-and-technology/20140710/Max-Philippines-Novartis-Healthcare.jpg ) [1] => Array ( [ArticleID] => 931772 [Title] => Novartis celebrates a decade of helping Filipino cancer patients [Summary] =>

More than 500 cancer patients, their families and caregivers recently gathered at Camp Aguinaldo in Quezon City to celebrate the 10th anniversary of the Novartis Oncology Access (NOA) program.

[DatePublished] => 2013-04-18 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 580426 [Title] => Novartis to continue helping poor patients [Summary] =>

Novartis Healthcare Phils. has reaffirmed its commitment to implement innovative programs designed to help underprivileged Filipino patients gain access to effective cancer treatments.

[DatePublished] => 2010-06-03 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>

MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
IMATINIB
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1344307
                    [Title] => Access program helps poor cancer patients get treatment
                    [Summary] => 

A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.

[DatePublished] => 2014-07-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => http://media.philstar.com/images/the-philippine-star/business/science-and-technology/20140710/Max-Philippines-Novartis-Healthcare.jpg ) [1] => Array ( [ArticleID] => 931772 [Title] => Novartis celebrates a decade of helping Filipino cancer patients [Summary] =>

More than 500 cancer patients, their families and caregivers recently gathered at Camp Aguinaldo in Quezon City to celebrate the 10th anniversary of the Novartis Oncology Access (NOA) program.

[DatePublished] => 2013-04-18 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 580426 [Title] => Novartis to continue helping poor patients [Summary] =>

Novartis Healthcare Phils. has reaffirmed its commitment to implement innovative programs designed to help underprivileged Filipino patients gain access to effective cancer treatments.

[DatePublished] => 2010-06-03 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>

MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with